Head-To-Head Comparison: aTyr Pharma (LIFE) versus Its Competitors
aTyr Pharma (NASDAQ: LIFE) is one of 198 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare aTyr Pharma to related businesses based on the strength of its risk, valuation, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Volatility and Risk
aTyr Pharma has a beta of 4.09, indicating that its stock price is 309% more volatile than the S&P 500. Comparatively, aTyr Pharma’s peers have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
This is a breakdown of recent recommendations for aTyr Pharma and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|aTyr Pharma Competitors||482||2273||6207||120||2.66|
aTyr Pharma currently has a consensus target price of $4.46, indicating a potential downside of 14.18%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.69%. Given aTyr Pharma’s peers stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma has less favorable growth aspects than its peers.
Earnings and Valuation
This table compares aTyr Pharma and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|aTyr Pharma||N/A||-$50.67 million||-2.39|
|aTyr Pharma Competitors||$207.79 million||-$2.30 million||2.07|
aTyr Pharma’s peers have higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares aTyr Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|aTyr Pharma Competitors||-3,950.55%||-117.51%||-43.69%|
Insider & Institutional Ownership
46.6% of aTyr Pharma shares are owned by institutional investors. Comparatively, 46.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 33.3% of aTyr Pharma shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
aTyr Pharma peers beat aTyr Pharma on 8 of the 12 factors compared.
aTyr Pharma Company Profile
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.